PRevalence of the Eosinophilic Phenotype Among SeveRE asthma patients in Lebanon: results of the PREPARE study
Authors:
- Wajdi Abi SalehWSWajdi Abi Saleh
- Zuhair AlamehZAZuhair Alameh
- Zeina Aoun BachaZBZeina Aoun Bacha
- Joudy BahousJBJoudy Bahous
- Pierre Bou KhalilPKPierre Bou Khalil
- Zahia ChahineZCZahia Chahine
- Hassan ChamiHCHassan Chami
- Georges DabarGDGeorges Dabar
- Hassan DheinyHDHassan Dheiny
- Alfred DibADAlfred Dib
- Dany FarhatDFDany Farhat
- Carla IraniCICarla Irani
Open Access
- 8 September 2023
- journal article
- research article
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 19 (1) , 1-9
Abstract
Background: The prevalence of eosinophilic asthma in Lebanon, one of the most severe phenotypes among severe asthma, is not known. This study aimed at determining the prevalence of the eosinophilic phenotype defined as an eosinophil count ≥ 300 cells/mm3 among severe asthma patients in Lebanon. Methods: The Lebanese Chapter of the PREPARE study was a national, multicenter, cross-sectional observational study. Patients aged ≥ 12 years with severe asthma were identified and prospectively enrolled during clinic visits and completed the Global Initiative for Asthma (GINA) assessment of asthma control questionnaire. Patients’ health characteristics were collected from medical records and blood samples were obtained for measurement of serum IgE levels and blood eosinophils count. Results: Overall, 101 patients (with mean age of 46.3 ± 17.0 years and 73.27% females) with severe asthma were included and, among them, 37% had eosinophilic phenotype, 67.3% had atopic phenotype with IgE > 100 IU/mL and 25.7% patients had overlapping atopic and eosinophilic phenotypes. Close to 80% had late-onset asthma, beyond 12 years of age, and around 85% had at least one severe exacerbation in the 12 months prior to study enrolment. The majority of participants [64.4%] had uncontrolled asthma, 24.7% had partially controlled symptoms and 10.9% had controlled symptoms. 19.8% of participants were on chronic oral corticosteroids, 78.2% had short course treatment of corticosteroids and all were prescribed a combination of inhaled corticosteroids and long-acting beta-agonist. Conclusions: The majority of patients with severe asthma were uncontrolled of which 37% present with an eosinophilic phenotype, which should be taken into consideration for better management of these patients in view of the novel phenotype-specific therapeutic options.Keywords
Funding Information
- AstraZeneca, Near-East
This publication has 36 references indexed in Scilit:
- Eosinophilic Inflammation in Allergic AsthmaFrontiers in Pharmacology, 2013
- Obesity and Asthma: An Inflammatory Disease of Adipose Tissue Not the AirwayAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Economic burden of asthma: a systematic reviewBMC Pulmonary Medicine, 2009
- Cluster Analysis and Clinical Asthma PhenotypesAmerican Journal of Respiratory and Critical Care Medicine, 2008
- The socio‐economic burden of asthma is substantial in EuropeAllergy, 2007
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Asthma and cigarette smokingEuropean Respiratory Journal, 2004
- Asthma exacerbations and sputum eosinophil counts: a randomised controlled trialThe Lancet, 2002
- Evidence That Severe Asthma Can Be Divided Pathologically into Two Inflammatory Subtypes with Distinct Physiologic and Clinical CharacteristicsAmerican Journal of Respiratory and Critical Care Medicine, 1999